| |
Letter to Providers: Mass Director of Pharmacy Referred HCV Drugs
|
| |
| |
Subject: Preferred Drugs- Hepatitis C Virus (HCV)
July 1, 2016
Key Points:
- Harvoni™ will be the preferred combination agent HCV medication
- Sovaldi™ and Daklinza™ will be the preferred single-agent HCV medications
- Current prior authorizations will be grandfathered for the life of the prior authorization
Dear Prescriber,
Effective July 1, 2016, MassHealth will be implementing Harvoni™ as its preferred combination agent and Sovaldi™ and Daklinza™ as preferred single agent HCV medications.
MassHealth will continue to cover non-preferred products when medically necessary and for members who currently have an approved prior authorization on file but have not yet completed therapy.
The MassHealth Preferred Drug List can be found at
https://masshealthdruglist.ehs.state.ma.us/MHDL/ .
Additional information about the coverage status and prior authorization criteria for Hepatitis Antiviral Agents can be found in Table 44 at
https://masshealthdruglist.ehs.state.ma.us/MHDL/pubtheradetail.do?id=52&drugId=4600
MassHealth anticipates that its Managed Care Organizations will provide guidance to prescribers in their networks regarding implementation of this preferred drug structure in the near future.
We appreciate your continued support and dedication to providing high quality care to MassHealth members.
|
|
| |
| |
|
|
|
